Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously approved by the boards of both companies and Novartis will pay $85 per share.
This takeover comes following The Medicines Company presenting the results of successful late stage trials of its cholesterol-lowering drug inclisiran this month.
